Drug Information

Drug General Information
Drug ID
D0I3VT
Former ID
DIB012104
Drug Name
CAD-106
Synonyms
Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis
Drug Type
Vaccine
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 2/3 [525332]
Company
Cytos Biotechnology AG
Target and Pathway
Target(s) Amyloid beta A4 protein Target Info [531529]
KEGG Pathway Notch signaling pathway
Alzheimer's disease
Reactome Nuclear signaling by ERBB4
Degradation of the extracellular matrix
Regulated proteolysis of p75NTR
NRIF signals cell death from the nucleus
Activated NOTCH1 Transmits Signal to the Nucleus
Constitutive Signaling by NOTCH1 PEST Domain Mutants
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
EPH-ephrin mediated repulsion of cells
WikiPathways Notch Signaling Pathway
Signaling by ERBB4
Signaling by NOTCH3
Signaling by NOTCH4
Signaling by NOTCH1
Signaling by NOTCH2
Notch Signaling Pathway
Alzheimers Disease
Signalling by NGF
References
Ref 525332ClinicalTrials.gov (NCT02565511) A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.
Ref 531529The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.